Previous 10 | Next 10 |
Aimed at boosting shareholder value, Zafgen (NASDAQ: ZFGN ) will explore strategic alternatives that could include a merger, business combination or in-licensing. More news on: Zafgen, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced plans to e...
Zafgen (NASDAQ: ZFGN ): Q2 GAAP EPS of -$0.32 beats by $0.04 . More news on: Zafgen, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the end of 2019 PATH for PWS study over-enrolled with continued stro...
Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the end of 2019 Company has implemented measures to ensure the effective use of ca...
BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffre...
Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data demonstrating that treatment with ZGN-1061 improves measures of insulin sensitivity and b...
Introduction Every year the Russell Indexes are rebalanced to bring in new stocks and remove underperforming stocks. The FTSE Russell calls this event the annual reconstitution process, and it begins with evaluations in May and moves to the selection process on June 7th with the newly recons...
Gainers: Obalon Therapeutics (NASDAQ: OBLN ) +42% . Eltek (NASDAQ: ELTK ) +35% . SilverSun Technologies (NASDAQ: SSNT ) +33% . MiMedx Group ( OTC:MDXG ) +31% . BioCryst Pharmaceuticals (NASDAQ: BCRX ) +19% . Tocagen (NASDAQ: TOCA ) +17% . Hydrogenics Corporation (NASDAQ: HYGS )...
J.Jill (NYSE: JILL ) -51% on Q1 earnings . More news on: J.Jill, Inc., Aptose Biosciences Inc., Eltek Ltd., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chi...
These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for Friedreich’s ataxia Companies to host confere...